<DOC>
	<DOCNO>NCT01754987</DOCNO>
	<brief_summary>This protocol phase I/II , study ascorbic acid ( AA ) infusion combine treatment sorafenib versus treatment sorafenib alone subject metastatic hepatocellular carcinoma . The phase I aspect assess safety efficacy concurrent treatment phase II aspect utilize CT ( computer-tomography ) scan assess overall tumor response rate evaluate disease progression</brief_summary>
	<brief_title>A Study Vitamin C Treatment Liver Cancer Determine Safe Effective</brief_title>
	<detailed_description>Intravenous Ascorbic Acid ( Vitamin C ) widely use alternative cancer treatment . This trial study intravenous Vitamin C treatment person liver cancer spread , also receive Sorafenib ( standard cancer drug ) , see whether combination Vitamin C Sorafenib safe well tolerate . Phase I involve 6 person receive Vitamin C 8 week specifically assess safety get Vitamin C combination Sorafenib . Phase II randomize receive either Vitamin C plus Sorafenib Sorafenib alone 16 week . If Vitamin C beneficial effect tumour cell , patient may experience regression tumor tumor marker . Additional benefit include scan charge patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Antineoplastic Agents , Phytogenic</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Age &gt; 18 year Metastatic hepatocellular carcinoma G6PD ( glucose6phosphate dehydrogenase ) status &gt; low limit normal Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Laboratory baseline evaluation inclusion study : creatinine ≤1.5X upper limit ( creatinine elevate , ≤1.5X ULN , 24 hour creatinine clearance obtain ) ; transaminase ( AST/ALT ) ≤2.0X upper limit normal ; bilirubin level ≥ 2 mg/dL ; ANC ≥1,500/mm3 ; Hemoglobin &gt; 8g/dL ; platelet ≥ 100,000/mm3 Women childbearing potential confirm negative pregnancy test must practice effective contraception study . Willing able provide inform consent participate study procedure . Patients evidence significant current psychiatric disorder would prevent completion study determine PI allow participate . Comorbid medical condition would affect survival tolerance determine PI . This include patient fully recovered toxicity associate prior therapy . It also include subject , determine PI , risk experience fluid overload ( i.e. , congestive heart failure ) . Patients currently abuse alcohol drug . Patients know glomerular filtration rate &lt; 60ml/min nephrotic range proteinuria . Pregnant lactate woman Enrollment active clinical trial/ experimental therapy IND study within prior 30 day . Contraindication CT PET/CT per PI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vitamins</keyword>
	<keyword>Malignant Tumor , Tumour</keyword>
	<keyword>Integrative Medicine</keyword>
	<keyword>Complementary Medicine</keyword>
	<keyword>Alternative Medicine Antioxidants</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Protective Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Micronutrients</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Antineoplastic Agents , Phytogenic</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Radiation-Sensitizing Agents</keyword>
	<keyword>Liver Cancer</keyword>
</DOC>